Lightspeed Early Access Program News Today

The global small-scale bioreactors market is predicted to register a CAGR of 14.8% over the forecast period, as per FMI’s analysis. The industry’s size is anticipated to increase from US$ 1.94 billion in 2023 to US$ 7.71 billion by 2033 end.New therapies are expected to be increasingly developed in the coming years...

In part 1 of this two-part article, Jason C. Foster, CEO and executive director of Ori Biotech, and Abe Maingi, VP of business development and...

The global small-scale bioreactors market is predicted to register a CAGR of 14.8% over the forecast period, as per FMI’s analysis. The industry’s size is anticipated to increase from US$ 1.94 billion in 2023 to US$ 7.71 billion by 2033 end.New therapies are expected to be increasingly developed in the coming years...

Ori Biotech (Ori), a leader in cell and gene therapy (CGT) manufacturing technologies, and the Cell Therapy Manufacturing Center (CTMC), a joint venture between National Resilience Inc and MD Anderson Cancer Center, today announce a collaborative partnership to develop industrial manufacturing processes for cell ...

Ori Biotech Ltd, an innovator in the cell and gene therapy (CGT) manufacturing sphere, has secured over US$100m in an oversubscribed Series B funding round.

LONDON, Jan. 18, 2022 /PRNewswire/ -- Ori Biotech Ltd. (Ori), a leader in cell and gene therapy (CGT) manufacturing technology, today announces it...

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

/PRNewswire/ -- Ori Biotech Ltd. (Ori), a leader in cell and gene therapy (CGT) manufacturing technology, today announces it has secured over $100 million in...